ADC Therapeutics SA Common Shares (ADCT) earnings
ADCT earnings moved a median of 0.00% by the close. Quarterly and annual ADCT reports and results, each read against the price at its own news timestamp. Back to the ADCT overview →
24 measured ADCT earnings events.
Where these ADCT earnings landedvs 23 measured ADCT earnings reactions
| Middle 50% of ADCT earnings reactions | -3.87% to +2.87% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 ADCT earnings events with a measured close landed between -3.87% and +2.87%; 43% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates | Press release | -4.66% | +5.00% | |
| Form 10-Q ADC Therapeutics SA For: Jun 30 | SEC filing · Form 10-Q | +0.49% | -0.98% | |
| ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 | Press release | +1.87% | +5.61% | |
| ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates | Press release | +2.10% | +2.79% | |
| Form 10-Q ADC Therapeutics SA For: Mar 31 | SEC filing · Form 10-Q | +2.41% | +0.80% | |
| ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 | Press release | +2.32% | -3.09% | |
| Form 10-K ADC Therapeutics SA For: Dec 31 | SEC filing · Form 10-K | +0.63% | +2.95% | |
| ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update | Press release | +4.96% | +4.47% | |
| Form 10-Q ADC Therapeutics SA For: Sep 30 | SEC filing · Form 10-Q | +0.72% | -4.80% | |
| ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 | Press release | +0.45% | -5.21% | |
| ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update | Press release | — | — | |
| Form 10-Q ADC Therapeutics SA For: Jun 30 | SEC filing · Form 10-Q | +1.33% | +3.00% | |
| ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 | Press release | +0.00% | -3.65% | |
| ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update | Press release | -0.49% | +27.46% | |
| Form 10-Q ADC Therapeutics SA For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -7.14% | |
| ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 | Press release | -3.91% | +0.00% | |
| Form 10-K ADC Therapeutics SA For: Dec 31 | SEC filing · Form 10-K | +0.00% | +2.01% | |
| Form 10-Q ADC Therapeutics SA For: Sep 30 | SEC filing · Form 10-Q | -0.29% | -2.98% | |
| ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 | Press release | +0.00% | -4.08% | |
| Form 10-Q ADC Therapeutics SA For: Jun 30 | SEC filing · Form 10-Q | +3.67% | -2.67% | |
| ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024 | Press release | -0.29% | +0.00% | |
| ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates | Press release | +4.85% | -7.68% | |
| Form 10-Q ADC Therapeutics SA For: Mar 31 | SEC filing · Form 10-Q | +4.85% | -7.68% | |
| Form 10-K ADC Therapeutics SA For: Dec 31 | SEC filing · Form 10-K | -1.17% | +1.56% |
Keep exploring
More ADCT: analyst actions → · SEC filings → · ADCT overview →